Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Ask Michael Burke -- Ignore unavailable to you. Want to Upgrade?

To: Knighty Tin who wrote (30055)	7/23/1998 11:19:00 AM
From: Knighty Tin	Respond to of 132070

To all, An excellent quarterly report from Genzl, belying the fall in the stock price. Revenues increased 60% and the net loss dropped about 8 1/2%. Sales of all products are growing rapidly and research on NeuroCell for Parkinson's is progressing, though slower than I had hoped. Investors may be daunted somewhat by the losses, but that is the way it works with new product biotech companies. There comes a time when products in the field overwhelm the cost of development in the labs, but that has not happened yet for Genzl. My main focus is that they seem to be making progress toward reaching that goal. MB